title: Enhancement of baicalin by hexamethylene bisacetamide on the induction of apoptosis contributes to simultaneous activation of the intrinsic and extrinsic apoptotic pathways in human leukemia cells.
abstract: Hexamethylene bisacetamide (HMBA) and natural flavanoid baicalin both exert potent antileukemic activity. However, there is currently no data on the anti-leukemic effects of baicalin in combination with HMBA. In the present study, we demonstrated that the combination of baicalin and HMBA synergistically inhibited the proliferation of acute myeloid leukemia (AML) cell lines. In addition, a slight G0/G1 phase arrest and significant apoptosis were observed. The combination treatment triggered apoptosis through the intrinsic pathway, which involved loss of MMP, decreased Bcl‑2/Bax ratio and Bcl‑XL/Bax ratio, caspase‑9 activation, as well as through the extrinsic pathway mediated by Fas and caspase‑8 activation. On the other hand, combination of baicalin and HMBA showed little toxic effect on peripheral blood mononuclear cells from healthy volunteers. Our results raise the possibility that the novel combination of baicalin and HMBA may be a promising regimen for the treatment of AML.
authors: Key Laboratory for Rare and Uncommon Diseases, Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong Province, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China.
authors: Xia
authors: X
authors: Ren
authors: Yubao
authors: Y
authors: Zhang
authors: Cuiling
authors: C
authors: Li
authors: Hengxiao
authors: H
authors: Wang
authors: Zheng
authors: Z
authors: Jiang
authors: Zhiyong
authors: Z
authors: Zhang
authors: Qiang
authors: Q
authors: Guo
authors: Guanhua
authors: G
authors: Song
authors: Kehong
authors: K
authors: Bi
authors: Guosheng
authors: G
authors: Jiang
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D053181:Caspase 8 / Q000378:metabolism; D053453:Caspase 9 / Q000378:metabolism; D045744:Cell Line, Tumor; D005419:Flavonoids / Q000008:administration & dosage*; D016193:G1 Phase / Q000187:drug effects; D064368:Healthy Volunteers; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D000081:Acetamides; D005419:Flavonoids; D051028:bcl-2-Associated X Protein; C038044:baicalin; D053181:Caspase 8; D053453:Caspase 9; C014026:hexamethylene bisacetamide